bezafibrate has been researched along with Fatty Liver, Nonalcoholic in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (75.00) | 24.3611 |
| 2020's | 2 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akahane, M; Habu, Y; Honda, A; Ishii, I; Kamata, S; Kaneko, C; Machida, Y; Miyawaki, S; Oyama, T; Shiiyama, Y; Uchii, K | 1 |
| Honda, A; Ishii, I | 1 |
| Chen, YH; Hu, P; Peng, ML; Ren, H; Zhan, Z | 1 |
| Ackerman, Z; Amir, G; Grozovski, M; Oron-Herman, M; Rosenthal, T; Sela, BA | 1 |
| Ackerman, Z; Ben-Ari, Z; Chepurko, Y; Cohen, M; Grossman, E; Hochhauser, E; Leibowitz, A; Schmilovitz-Weiss, H; Yitzhaki, S | 1 |
| Aichler, M; Brachthäuser, L; Feuchtinger, A; Franko, A; Fuchs, H; Häring, HU; Hrabě de Angelis, M; Kovarova, M; Neff, F; Neschen, S; Peter, A; Rathkolb, B; Rozman, J; Wolf, E | 1 |
| Aburada, M; Hokao, R; Iizuka, S; Makihara, H; Sasaki, Y; Shimada, T; Suzuki, W; Teraoka, R; Tsuneyama, K | 1 |
| Katsuya, T; Kiomy Osako, M; Koriyama, H; Kyutoku, M; Minobe, N; Miyake, T; Morishita, R; Moritani, T; Nakagami, F; Nakagami, H; Shimamura, M; Shimizu, H; Shimosato, T | 1 |
1 review(s) available for bezafibrate and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
[The Perspective of PPAR Dual/Pan Agonists as Therapeutic Drugs against NAFLD].
Topics: Bezafibrate; Humans; Hypoglycemic Agents; Non-alcoholic Fatty Liver Disease; Obesity; PPAR alpha | 2022 |
7 other study(ies) available for bezafibrate and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
Functional and Structural Insights into Human PPARα/δ/γ Subtype Selectivity of Bezafibrate, Fenofibric Acid, and Pemafibrate.
Topics: Benzoxazoles; Bezafibrate; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofibrate; Humans; Ligands; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR delta; PPAR gamma | 2022 |
[A new attempt with lipoprotein lipase agonists in the treatment of nonalcoholic steatohepatitis].
Topics: Bezafibrate; Biopsy; Carboxylic Acids; Case-Control Studies; Computational Biology; Enzyme Activators; Gemfibrozil; Glycyrrhizic Acid; Humans; Lipid Metabolism; Lipoprotein Lipase; Non-alcoholic Fatty Liver Disease; Oligonucleotide Array Sequence Analysis; Scavenger Receptors, Class E | 2019 |
Effects of antihypertensive and triglyceride lowering agents on splenocyte apoptosis in rats with fatty liver.
Topics: Amlodipine; Animals; Antihypertensive Agents; Apoptosis; Bezafibrate; Blood Pressure; Captopril; Caspase 3; Fatty Liver; Hypolipidemic Agents; Lipids; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Rats; Rats, Sprague-Dawley; Spleen; Triglycerides | 2013 |
Rosiglitazone and bezafibrate modulate gene expression in a rat model of non-alcoholic fatty liver disease--a historical prospective.
Topics: Animals; Bezafibrate; Disease Models, Animal; Fatty Liver; Fructose; Gene Expression; Hypoglycemic Agents; Hypolipidemic Agents; Liver; Male; Non-alcoholic Fatty Liver Disease; PPAR alpha; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Superoxide Dismutase; Thiazolidinediones | 2013 |
Bezafibrate ameliorates diabetes via reduced steatosis and improved hepatic insulin sensitivity in diabetic TallyHo mice.
Topics: Animals; Bezafibrate; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Experimental; Disease Models, Animal; Fatty Liver; Glucose; Hypolipidemic Agents; Insulin; Insulin Resistance; Lipid Metabolism; Liver; Male; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Peroxisome Proliferator-Activated Receptors | 2017 |
Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
Topics: Adipose Tissue; Animals; Bezafibrate; Diabetes Mellitus; Disease Models, Animal; Eating; Fatty Liver; Gene Expression Regulation; Glucose Tolerance Test; Glycosuria; Hypolipidemic Agents; Lipid Metabolism; Liver; Male; Metabolic Syndrome; Mice; Non-alcoholic Fatty Liver Disease; Obesity; Organ Size; RNA, Messenger; Sodium Glutamate | 2011 |
Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet.
Topics: Alanine Transaminase; Animals; Bezafibrate; Calcium Channel Blockers; Choline Deficiency; Diet; Disease Models, Animal; Fatty Liver; Hypolipidemic Agents; Liver; Liver Cirrhosis, Experimental; Male; Methionine; Nifedipine; Non-alcoholic Fatty Liver Disease; PPAR gamma; Rats; Rats, Wistar | 2012 |